Host response testing allows physicians to quickly rule out entire categories of potential infection to narrow their focus to the likely culprits for an illness. This can enable physicians to make faster, more accurate diagnoses — which, in turn, can significantly improve overall global public health through more efficient treatments, reduced hospital stays, and more efficient delivery of care.
In this exploration, we delve into three main values that redefine healthcare outcomes, combining insights from Biomeme’s commitment to swift and accurate diagnosis, overcoming conventional test shortcomings, and enhancing cost-efficiency in healthcare.
Prompt and Accurate Diagnosis for Informed Antibiotic Prescriptions |
Nobody enjoys a sick visit to the doctor or urgent care. The faster they can get their test results, the better. A state-of-the-art diagnostic platform, like HR-B/V, enables healthcare professionals to rapidly rule out potential infections, usering in a new era of faster and more accurate diagnoses.
A test like HR-B/V not only saves time for physicians and patients but also ensures antibiotics are prescribed only when necessary. This proactive approach addresses antibiotic misuse, contributes to global antibiotic stewardship efforts, and preserves the efficacy of antibiotics for severe bacterial infections.
Biomeme’s Director of Marketing and Product Tom Cook says,
“In common scenarios like Fever of Unknown Origin, HR-B/V can help get to the root of the cause faster than ever, and patients can rest assured that they are getting the best care possible.”
Enhancing Cost-Efficiency in Healthcare |
A standout feature of our HR-B/V platform is its potential to significantly reduce healthcare costs. By streamlining diagnostic processes, the platform minimizes clinic visits, associated costs, and unnecessary medical resource utilization. Biomeme’s commitment to cost-efficiency extends to curtailing prescription costs, preventing the unnecessary use of antibiotics, and actively contributing to mitigating the financial burden on healthcare systems.
Biomeme’s VP of Sales, Joe Tumolo says,
“Adopting a host response approach, such as with the HR-B/V test, aligns with the clinical reality. In laboratories, the strain on staffing is evident, especially when inundated with numerous pathogen-based diagnostic tests. Our test streamlines this process, eliminating unnecessary tests and optimizing staff time. This shift allows laboratories to focus on essential tests crucial for patient care, offering a more efficient and clinically sensible approach in the face of staffing challenges.”
|
Overcoming Conventional Test Shortcomings |
Traditional diagnostic methods often fall short in distinguishing bacterial and viral infections, leading to delays, inaccuracies, and unnecessary costs. Biomeme’s HR-B/V platform excels in early detection and non-invasive sampling, surpassing limitations of conventional tests. The Franklin ISP® versatility and the gold-standard PCR employed in the HR-B/V test provide reliable diagnostics, enhancing infection identification and addressing the shortcomings of outdated technologies.
In essence, Biomeme's HR-B/V platform is not merely a diagnostic tool but a comprehensive solution reshaping healthcare outcomes. It ensures accuracy, accelerates diagnosis, and actively contributes to a more efficient and cost-effective healthcare environment. If you're eager to explore the transformative potential of Biomeme's platform, we invite you to reach out. Let's collaborate to propel healthcare into a future where precision, efficiency, and cost-effectiveness define the new standard.
Products currently under development and not approved/cleared by the FDA.